Sangi Co., Ltd.   Report issue

For profit Phase 2
Founded: Tokyo Japan (1974)
Status: No NME R&D (1974)

Organization Overview

First Clinical Trial
2015
NCT02918617
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Sangi Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

nanohydroxyapetite (1 trial)

sodium fluoride (18F) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dentin Sensitivity (Phase 2)

Hypersensitivity (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2